To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

TKA: Minimally invasive subvastus approach yields no gait or strength benefit at 2 months

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
April 2013

TKA: Minimally invasive subvastus approach yields no gait or strength benefit at 2 months

Vol: 2| Issue: 3| Number:16| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

The John Insall award: no benefit of minimally invasive TKA on gait and strength outcomes: a randomized controlled trial

Clin Orthop Relat Res. 2013 Jan;471(1):46-55. doi: 10.1007/s11999-012-2486-1

Contributing Authors:
J Wegrzyn S Parratte K Coleman-Wood KR Kaufman MW Pagnano

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

40 patients scheduled for primary total knee arthroplasty (TKA) were assessed for eligibility and 37 were randomized to receive the minimally invasive subvastus approach or standard medial parapatellar TKA technique in order to compare outcomes after 2 months. Subjective function and quality of life, return to normal activities of daily living, quadriceps strength and gait kinematics were assessed...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue